In conclusion, we suggest that modulation of eIF6 levels and activity may lead to a therapeutical avenue in tumor therapy, especially where eIF4E inhibition by rapalogs is not effective, as in malignant mesothelioma [29, 30]. Here, EIF6 is linked to neoplasm.